Argos Therapeutics withdraws IPO

By
A A A

Argos Therapeutics, which is developing personalized immunotherapies for metastatic renal cancer and HIV, withdrew its plans for an initial public offering on Tuesday because of poor market conditions. The Durham, NC-based company was founded in 1997 and has yet to generate any product revenue. Lazard Capital Markets and Canaccord Genuity were set to be the lead underwriters on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , IPOs

Referenced Stocks: ARGS

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com